Floxin

(Ofloxacin)

ApprovedSmall molecule

WWim Janssens

Floxin is one of 138 small molecule programs targeting Pelvic Inflammatory Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

137

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Pelvic Inflammatory DiseaseActive, not recruiting

MyopiaActive, not recruiting

ToxicityActive, not recruiting

CataractActive, not recruiting

PeriodontitisActive, not recruiting

Multiple MyelomaActive, not recruiting

Pelvic Inflammatory DiseasePhase 3

Active, not recruiting

MyopiaPreclinical

Active, not recruiting

ToxicityPreclinical

Active, not recruiting

CataractPhase 3

Active, not recruiting

PeriodontitisApproved

Active, not recruiting

Multiple MyelomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Floxin

WWim Janssens

Approved

1 2

Ninlaro

Takeda

Preclinical

18 3

Prolia

Amgen

Preclinical

5 4

Eliquis

Bristol-Myers Squibb

Preclinical

3 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 6

Adriamycin

GGynecologic Oncology Group

Preclinical

9 7

Nolvadex

AstraZeneca

Preclinical

1 8

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 9

Intron a

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

N/ARecruiting

Toxicity

NCT04496024

Q4 2028

Phase 3Recruiting

CAR

NCT03933631

Clinical

Trials by Indication[1]

Diabetic Ulcer2 trials

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

Completed·AAbeona Therapeutics, Inc·Phase 3·NCT00563433·342 enrolled

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

Completed·AAbeona Therapeutics, Inc·Phase 3·NCT00563394·584 enrolled

Pelvic Inflammatory Disease2 trials

Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.

Completed· Bayer logo

Bayer·Phase 3·NCT00683865·749 enrolled

Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials

Completed·IIstanbul Bakirkoy Maternity and Children Diseases Hospital·Phase 4·NCT01799356·1,303 enrolled

Trial1 trial

Descemet Endothelial Thickness Comparison Trial

Unknown status·OOregon Health and Science University·Phase 4·NCT02373137·38 enrolled

Antibiotics1 trial

Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome

Recruiting·—·Phase 1·NCT05302531·10 enrolled

Cataract1 trial

Pilocarpine After Combined Cataract/Trabectome Surgery

Withdrawn·MMontefiore Medical Center·Phase 3·NCT04005079

8 more indications

Myopia1 trial

VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia

Completed·LLondon Vision Clinic·N/A·NCT02528123·114 enrolled

Multiple Myeloma1 trial

Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy

Completed·GGary Morrow·Phase 3·NCT00002850·212 enrolled

Prophylaxis1 trial

Ofloxacin vs. Gentamicin as Prophylaxis Prior Transrectal Biopsy of Prostate

Unknown status·HHaEmek Medical Center, Israel·Phase 4·NCT00480376·160 enrolled

Periodontitis1 trial

Alternative Antibiotic Regimen in Periodontitis Treatment

Completed·IIstanbul Medipol University Hospital·Phase 4·NCT04353362·74 enrolled

CAR1 trial

Pilocarpine Use After Kahook Goniotomy

Recruiting·MMontefiore Medical Center·Phase 3·NCT03933631·142 enrolled

Toxicity1 trial

Ofloxacin Concentration-toxicity Relationship in the Elderly

Recruiting·—·N/A·NCT04496024·110 enrolled

Pregnancy1 trial

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)··NCT00042289·1,578 enrolled

Fluoroquinolone1 trial

Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs

Completed·IIndiana University School of Medicine·Phase 4·NCT00392275·48 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 28, 1990

FLOXIN

NDA NDA019735

Mar 31, 1992

FLOXIN

NDA NDA020087

Jul 30, 1993

OCUFLOX

NDA NDA019921

Dec 16, 1997

FLOXIN OTIC

NDA NDA020799

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Ofloxacin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ofloxacin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ofloxacin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020799). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Wim Janssens company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: WWim Janssens

Floxin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2028

Trials by Indication[1]

Diabetic Ulcer2 trials

Pelvic Inflammatory Disease2 trials

Trial1 trial

Antibiotics1 trial

Cataract1 trial

Myopia1 trial

Multiple Myeloma1 trial

Prophylaxis1 trial

Periodontitis1 trial

CAR1 trial

Toxicity1 trial

Pregnancy1 trial

Fluoroquinolone1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News